Immunotherapy after salvage surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests an immunotherapy given after salvage surgery for certain head and neck squamous cell cancers that came back (or a new second cancer) in an area that was already treated with radiation. It aims to lower the chance the cancer returns after surgery, especially in higher-risk situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your head and neck squamous cell cancer is a recurrence or a second primary in a previously irradiated area (radiation dose was at least 50 Gy).
- You had salvage surgery intended to fully remove the visible tumor, and the surgeon could remove it completely (no leftover visible cancer).
- You start the study treatment within 8 weeks (plus or minus 2 weeks) after your salvage surgery once you are healed enough.
- Scans (CT or PET) show no distant spread (no metastases).
- Your blood counts and organ tests are strong enough (for example, white blood cells and platelets must be above set thresholds, and kidney and liver tests must be acceptable).
- You can stop steroid medicines that suppress the immune system at least 2 weeks before the study treatment, and you don’t have certain immune problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
This trial compares two immunotherapy drugs (ivonescimab and pembrolizumab) given with standard chemotherapy before and possibly after surgery for advanced head and neck cancer that can be removed. The aim is to see which drug is better at shrinking the tumor and improving outcomes.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.